Inclusion Criteria:  Patient has diagnosis of pancreatic adenocarcinoma with documented metastatic disease. Patient progressed after gemcitabine-based therapy. Patient received at least one treatment cycle with Onivyde® + 5-FU/LV 5FU in the context of post-gemcitabine based therapy of mPDAC.  Exclusion Criteria:  Patient has not received at least one treatment cycle with Onivyde® + 5-FU/LV. Previous irinotecan-based therapy in metastatic setting. Patientstarted the treatment with Onivyde® + 5-FU/LV after 1/11/2020.